Su Xin, Nickles Angela, Nelson Dwight E
Medtronic plc, Neuromodulation Research, 7000 Central Avenue, Minneapolis, MN, 55432, USA.
Physiological Research Laboratories, 7000 Central Avenue, Minneapolis, MN, 55432, USA.
BMC Urol. 2015 Jun 9;15:50. doi: 10.1186/s12894-015-0048-z.
While botulinum toxin A (BoNT-A) has become a more commonly used second-line treatment for patients with detrusor overactivity, it remains unknown whether the impacts of this therapy may persist to influence other therapies such as sacral neuromodulation. In this preclinical study we have evaluated urodynamic functions to intradetrusor injection of BoNT-A and the bladder inhibitory effects of spinal nerve stimulation (SNS) following BoNT-A treatment.
Female rats were anesthetized with 3 % isoflurane. BoNT-A (2 units, 0.2 ml) or saline were injected into the detrusor. Rats then were housed for 2 days to 1 month before neuromodulation study. Monopolar electrodes were placed under each of the L6 spinal nerve bilaterally under urethane anesthesia. A bladder cannula was inserted via the urethra for saline infusion and intravesical pressure recording.
Intradetrusor injection of BoNT-A for 1-2 weeks or 1 month significantly increased bladder capacity compared with saline injection (p < 0.05, two-way ANOVA). Following BoNT-A, SNS attenuated the frequency of bladder contractions, either eliminating bladder contractions or reducing the contraction frequency during electrical stimulation. Inhibition of the contraction frequency by SNS following BoNT-A treated rats was not different from that measured following saline injection.
BoNT-A increased the bladder capacity, but compensating for additional saline infusion to the enlarged urinary bladder in BoNT-A pretreated rats, the bladder contractions induced by bladder filling were attenuated by SNS. BoNT-A did not alter the ability of SNS to inhibit bladder contraction following intradetrusor injection of BoNT-A for 2 days, 1-2 weeks or 1 month. These results support further pre-clinical and clinical studies to evaluate potential interactions or combination therapy with neuromodulation and intradetrusor BoNT-A therapeutic approaches.
虽然肉毒杆菌毒素A(BoNT-A)已成为治疗逼尿肌过度活动患者更常用的二线治疗方法,但该疗法的影响是否会持续影响其他疗法,如骶神经调节,仍不清楚。在这项临床前研究中,我们评估了向逼尿肌内注射BoNT-A后的尿动力学功能,以及BoNT-A治疗后脊髓神经刺激(SNS)对膀胱的抑制作用。
用3%异氟醚麻醉雌性大鼠。将BoNT-A(2单位,0.2毫升)或生理盐水注入逼尿肌。然后将大鼠饲养2天至1个月,再进行神经调节研究。在氨基甲酸乙酯麻醉下,将单极电极双侧置于L6脊髓神经下方。通过尿道插入膀胱插管,用于盐水灌注和膀胱内压记录。
与注射生理盐水相比,向逼尿肌内注射BoNT-A 1至2周或1个月可显著增加膀胱容量(p<0.05,双向方差分析)。注射BoNT-A后,SNS减弱了膀胱收缩频率,要么消除膀胱收缩,要么在电刺激期间降低收缩频率。BoNT-A治疗的大鼠在SNS作用下收缩频率的抑制与注射生理盐水后测得的结果无差异。
BoNT-A增加了膀胱容量,但在给预先接受BoNT-A治疗的大鼠扩大的膀胱额外注入生理盐水时,SNS减弱了膀胱充盈引起的膀胱收缩。在向逼尿肌内注射BoNT-A 2天、1至2周或1个月后,BoNT-A并未改变SNS抑制膀胱收缩的能力。这些结果支持进一步开展临床前和临床研究,以评估神经调节与逼尿肌内BoNT-A治疗方法之间的潜在相互作用或联合治疗。